The Committee for Medicinal Products for Human Use has recommended marketing authorisation for Kostaive, a self-replicating mRNA (“saRNA”) injection developed by Arcturus Therapeutics. The final decision for regulatory approval now rests with the European Commission. The European Commission must reject authorisation for these dangerous saRNA (replicon) vaccines.